Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Community Practice Connections™: Advancing CAR T-Cell Therapies in Oncology Care

Release Date: April 30, 2019
Expiration Date: April 30, 2020
Media: Internet - based

Activity Overview

Community Practice Connections: Advancing CAR T-Cell Therapies in Oncology Care consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

CME Activity Table of Contents

  • Module 1. Introduction to CAR T-Cell Therapy
  • Module 2. A Patient With Relapsed DLBCL
  • Module 3. A Patient With Refractory Pre–B-Cell ALL
  • Module 4. Development of CAR T Cells in Patients With Multiple Myeloma
  • Module 5. Grading of CRS and Neurotoxicity

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals involved in the treatment and management of patients with hematologic malignancies may also participate.

Learning Objectives

Upon successful completion of this educational program, you should be better prepared to:

  • Explain the mechanism of action of CAR T cells in hematologic malignancies and differentiate among available and emerging therapies
  • Describe the manufacturing of CAR T cells and the standards under which manufacturing is conducted
  • Discuss recent clinical trial data concerning the application of CAR-T cell strategies in the context of evolving treatment paradigms for hematologic malignancy management
  • Delineate appropriate techniques to identify and manage different treatment-related toxicities in the care of patients who receive CAR-T cell therapies

Faculty, Staff, and Planners’ Disclosures

Andre H. Goy
Andre H. Goy, MD, MS
Chairman and Executive Director
Lymphoma Division Chief, John Theurer Cancer Center
Chief Science Officer, RCCA
Lydia Pfund Chair for Lymphoma
Professor of Medicine, Georgetown University
Hackensack, NJ

Disclosures: Grant/Research Support: Johnson & Johnson, Celgene, Gilead/Kite clinical trial support through institution; Consultant: Celgene; Speakers Bureau: Takeda, Johnson & Johnson/Pharmacyclics, Gilead/Kite; Shareholder: Cota Healthcare; Other: Member on advisory board: Cota Healthcare, Celgene, Takeda, Pharmacyclics, Johnson & Johnson, Acerta, Gilead/Kite.

Frederick L. Locke
Frederick L. Locke, MD
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Co-Leader, Moffitt Immunology Research Program
Research Director and Medical Director, Immune Cell Therapy Program
Moffit Cancer Center
Tampa, FL

Disclosure: Consultant: Cellular Biomedicine Group Inc.; Other: Member on advisory board: Novartis, Kite.

Jae H. Park
Jae H. Park, MD
Assistant Attending Physician
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Genentech, Juno Therapeutics, Amgen; Consultant: Amgen, Novartis, Pfizer, Kite Pharma, Bayer, Shire, Adaptive Biotechnologies, AstraZeneca, Obsidian Therapeutics, TG Therapeutics, Takeda.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By